NEW YORK (GenomeWeb News) - Roche Diagnostics today said it has signed a licensing agreement with Multilyte for access to Multilyte's patents for diagnostic assays.
 
Roche will pay a license fee and royalties from the sale of products covered by Multilyte’s patents.
 
Assays covered under the patents include mulitparameter binding assays, including immunoassays, to enable “simultaneous detection and analysis of many different analytes in small test samples of biological origin,” Roche said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.